Astremiha Therapeutics
PrivateLast Round
Early Funding
Jul 1, 2026
Total Funding Raised
$1,126
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Astremiha Therapeutics is a biotechnology company developing broad-spectrum, host-directed antivirals designed to block viral replication and strengthen the immune system to combat chronic viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Astremiha Therapeutics Comparables
Compare Astremiha Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Meletios Therapeutics | 83% | |
| Evrys Bio | 77% | |
| Kimer Med | 77% |
Astremiha Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jul 1, 2026 | ||||
| Seed | Jan 15, 2026 |
Astremiha Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Paris Biotech Santé | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2026
Raised $2.85M in early funding.
- Jan 15, 2026
$1K Seed round completed.
Astremiha Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access